Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Tratamiento con bifosfonatos para niños y adolescentes con osteoporosis secundaria

Información

DOI:
https://doi.org/10.1002/14651858.CD005324.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 17 octubre 2007see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Salud musculoesquelética

Copyright:
  1. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Leanne Ward

    Correspondencia a: Department of Pediatrics, University of Ottawa, Children's Hospital of Eastern Ontario, Ottawa, Canada

    [email protected]

  • Andrea Tricco

    PhD Program in Population Health, University of Ottawa, Ottawa, Canada

  • Phuc‐Nhi Phuong

    Pediatric Bone Research Program, Children's Hospital of Eastern Ontario, Ottawa, Canada

  • Ann Cranney

    Division of Rheumatology, Ottawa Hospital, Ottawa, Canada

  • Nick Barrowman

    Clinical Research Unit, Children's Hospital of Eastern Ontario Research Insitute, Ottawa, Canada

  • Isabelle Gaboury

    Clinical Research Unit, Children's Hospital of Eastern Ontario, Ottawa, Canada

  • Frank Rauch

    Genetics Unit, Shriners Hospital for Children, Montreal, Canada

  • Peter Tugwell

    Centre for Global Health, Institute of Population Health, Department of Medicine, Ottawa Hospital, Ottawa, Canada

  • David Moher

    Ottawa Hospital Research Institute, Ottawa, Canada

Contributions of authors

LW ‐ conceptualized the protocol, drafted the initial protocol and supervised all stages of the protocol refinement, drafted the final review
ACT, PP ‐ conducted the literature searches, drafted, refined and prepared the protocol for submission, extracted all data, drafted the final review, independently assessed study quality for each trial
FR, AC, PT, DM ‐ contributed to the conceptualization and refinement of the protocol, reviewed final manuscript
NB ‐ provided expertise on statistical appropriateness of individual trials, and independently assessed study quality for each trial, reviewed final manuscript
IG ‐ provided feedback on the clinical relevance table and expertise on statistical issues related to combining the trials

Sources of support

Internal sources

  • Children's Hospital of Eastern Ontario Research Institute (LMW, PNP), Canada.

External sources

  • Canadian Institutes for Health Research (LMW, ACT, AC), Canada.

  • Shriner's of North America (FR), USA.

  • Canadian Child Health Clinical Scientist Program (LMW), Canada.

  • University of Ottawa Research Chair (DM), Canada.

Declarations of interest

Leanne Ward and Frank Rauch have been co‐applicants in the past on operating grants from Merck‐Frost & Co to study alendronate, Novartis to study zoledronate and Proctor and Gamble to study risedronate, among patients with OI. Dr. Ward has also been a site investigator on an operating grant from Merck‐Frost & Co to investigate the pharmacokinetics and safety of alendronate among children with steroid‐induced osteoporosis.

Andrea C. Tricco has been a paid consultant for GlaxoSmithKline's non‐bisphosphonate related products.

Phuc‐Nhi Phuong ‐ none declared.

Ann Cranney has been a Consultant on the Merck Osteoporosis Medical Advisory Board and has received research funds from Merck for research to evaluate care gap in the treatment of older adults with fractures.

Nick Barrowman ‐ none declared.

Isabelle Gaboury ‐ none declared.

Peter Tugwell has been a paid consultant for Merck Frost. Please see the CMSG website www.cochranemsk.org for a detailed declaration of interest statement.

David Moher ‐ none declared.

Acknowledgements

The authors would like to thank Louise Falzon of the Cochrane Musculoskeletal Group for her assistance in developing the search strategy, Isabelle French for her contribution to the development of the protocol, Siobhan O'Donnell for her guidance on data extraction and data presentation, and Margaret Sampson for verifying the literature searches.

Version history

Published

Title

Stage

Authors

Version

2007 Oct 17

Bisphosphonate therapy for children and adolescents with secondary osteoporosis

Review

Leanne Ward, Andrea Tricco, Phuc‐Nhi Phuong, Ann Cranney, Nick Barrowman, Isabelle Gaboury, Frank Rauch, Peter Tugwell, David Moher

https://doi.org/10.1002/14651858.CD005324.pub2

2005 Apr 20

Bisphosphonate therapy for osteoporosis in children and adolescents without osteogenesis imperfecta

Protocol

Leanne Ward, Phuc‐Nhi Phuong, Frank Rauch, Ann Cranney, Peter Tugwell, David Moher

https://doi.org/10.1002/14651858.CD005324

Differences between protocol and review

Since the protocol, the primary outcomes were categorized into efficacy and harms. Patients with idiopathic juvenile osteoporosis (IJO) have been excluded from the review, due to the small numbers of retrieved studies. The title of the review was subsequently revised to include only children and adolescents with secondary osteoporosis. Additionally, distal femur changes were added to the first primary outcome, total participants were added to the fifth primary outcome, and linear growth was added to the secondary outcomes. Another reviewer (NB) assisted with quality assessments. Two reviewers were added (ACT, IG).